RAB27A and brain neoplasm: We aimed to replace endogenous Rab27-proficient (or -deficient) bone marrow cell populations that give rise to hematopoietic effector cells (platelets and myeloid cells) with their respective Rab27-deficient (or -proficient) counterparts to correspondingly induce (or prevent) brain tumor vascular dysmorphia (fig.